Serum Proteomic Profiling Reveals Differentially Expressed IGHG3 and A1AG1 as Potential Predictors of Chemotherapeutic Response in Advanced Non-small Cell …
MM Mon, C Srisomsap… - Anticancer …, 2021 - ar.iiarjournals.org
Background: This study aimed to identify differentially expressed proteins in the serum of
advanced non-small cell lung cancer (NSCLC) patients responding to carboplatin (CAR) …
advanced non-small cell lung cancer (NSCLC) patients responding to carboplatin (CAR) …
Identification of α1-antitrypsin as a potential prognostic biomarker for advanced nonsmall cell lung cancer treated with epidermal growth factor receptor tyrosine kinase …
W Zhao, Z Yang, X Liu, Q Tian, Y Lv… - Journal of …, 2013 - journals.sagepub.com
Objective This retrospective study attempted to identify serum biomarkers that could help to
indicate treatment response in advanced nonsmall-cell lung cancer (NSCLC) patients …
indicate treatment response in advanced nonsmall-cell lung cancer (NSCLC) patients …
[HTML][HTML] Identification of proteins deregulated by platinum-based chemotherapy as novel biomarkers and therapeutic targets in non-small cell lung cancer
Platinum-based chemotherapy remains the cornerstone of treatment for most people with
non-small cell lung cancer (NSCLC), either as adjuvant therapy in combination with a …
non-small cell lung cancer (NSCLC), either as adjuvant therapy in combination with a …
Serum α-1 acid glycoprotein is a biomarker for the prediction of targeted therapy resistance in advanced EGFR-positive lung adenocarcinoma
YF Xu, Y Xu, X Li, XM Yang - Combinatorial Chemistry & High …, 2018 - ingentaconnect.com
Objective: To determine the levels of α-1 acid glycoprotein (ORM1) in the sera of advanced
lung adenocarcinoma (LUAD) patients with epidermal growth factor receptor (EGFR) …
lung adenocarcinoma (LUAD) patients with epidermal growth factor receptor (EGFR) …
[HTML][HTML] From proteomic analysis to potential therapeutic targets: functional profile of two lung cancer cell lines, A549 and SW900, widely studied in pre-clinical …
L Korrodi-Gregorio, V Soto-Cerrato, R Vitorino… - PLoS …, 2016 - journals.plos.org
Lung cancer is a serious health problem and the leading cause of cancer death worldwide.
The standard use of cell lines as in vitro pre-clinical models to study the molecular …
The standard use of cell lines as in vitro pre-clinical models to study the molecular …
Screening anlotinib responders via blood‐based proteomics in non‐small cell lung cancer
J Lu, W Zhang, K Yu, L Zhang, Y Lou, P Gu… - The FASEB …, 2022 - Wiley Online Library
Anlotinib has been demonstrated to be effective in advanced non‐small cell lung cancer
(NSCLC) patients. The response stratification of anlotinib remains unclear. In this study …
(NSCLC) patients. The response stratification of anlotinib remains unclear. In this study …
[HTML][HTML] Screening and validation of significant genes with poor prognosis in pathologic stage-I lung adenocarcinoma
Y Deng, X Chen, C Huang, J Song, S Feng… - Journal of …, 2022 - hindawi.com
Background. Although more pathologic stage-I lung adenocarcinoma (LUAD) was
diagnosed recently, some relapsed or distantly metastasized shortly after radical resection …
diagnosed recently, some relapsed or distantly metastasized shortly after radical resection …
[HTML][HTML] Identification of Ubiquitin-Related Gene-Pair Signatures for Predicting Tumor Microenvironment Infiltration and Drug Sensitivity of Lung Adenocarcinoma
Y Li, L An, Z Jia, J Li, E Zhou, F Wu, Z Yin, W Geng… - Cancers, 2022 - mdpi.com
Simple Summary Lung adenocarcinoma (LUAD) has a high mortality and incidence rate.
The therapeutic efficacy of LUAD varies with the individual heterogeneity of the tumor …
The therapeutic efficacy of LUAD varies with the individual heterogeneity of the tumor …
Proteomics analysis of human serum of patients with non‐small‐cell lung cancer reveals proteins as diagnostic biomarker candidates
M Boccellino, F Pinto, V Ieluzzi… - Journal of Cellular …, 2019 - Wiley Online Library
Non‐small‐cell lung carcinomas (NSCLC) is the most common type of lung cancer and it
has a poor prognosis, because overall survival after 5 years is 20–25% for all stages. Thus …
has a poor prognosis, because overall survival after 5 years is 20–25% for all stages. Thus …
SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase …
It has been shown that a proteomic algorithm based on 8 MALDI TOF MS signals obtained
from plasma of NSCLC patients treated with EGFR TKIs, is able to predict patients' clinical …
from plasma of NSCLC patients treated with EGFR TKIs, is able to predict patients' clinical …